Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5073 Target Snapshot

Calcium/calmodulin-dependent protein kinase type 1D · SINGLE PROTEIN · Homo sapiens

1,523Compounds
274Assays
12Approved Drugs
676.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q8IU85. Use UniProt Q8IU85 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q8IU85 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Calcium/calmodulin-dependent protein kinase type 1D as ChEMBL target CHEMBL5073, mapped to UniProt Q8IU85. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Calcium/calmodulin-dependent protein kinase type 1D
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5073
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q8IU85
Calcium/calmodulin-dependent protein kinase type 1D
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Calcium/calmodulin-dependent protein kinase type 1D is the right protein anchor across sources, using UniProt Q8IU85 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCalcium/calmodulin-dependent protein kinase type 1D
UniProt AccessionQ8IU85
Component TypeProtein
Sequence Length385 aa

Calcium/calmodulin-dependent protein kinase type 1D

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Calcium/calmodulin-dependent protein kinase type 1D, mapped to UniProt Q8IU85. Sequence length is 385 aa.

Mapped IDQ8IU85
Review nameCalcium/calmodulin-dependent protein kinase type 1D
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

12
Approved
2
Phase III
8
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC50178.0
KI356.0
KD142.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.69 IC50 0.206 Preclinical
CHEMBL388978 8.96 Kd 1.1 Preclinical
CHEMBL5753821 8.4 IC50 4.0 Preclinical
CHEMBL6043667 8.4 IC50 4.0 Preclinical
CHEMBL1980995 8.4 Ki 3.981 Preclinical
CHEMBL5826196 8.3 IC50 5.0 Preclinical
CHEMBL5918789 8.3 IC50 5.0 Preclinical
CHEMBL5826007 8.22 IC50 6.0 Preclinical
CHEMBL5996247 8.22 IC50 6.0 Preclinical
CHEMBL6050954 8.22 IC50 6.0 Preclinical
Distribution

pChEMBL Value Distribution

14
5.0
41
5.5
66
6.0
41
6.5
38
7.0
35
7.5
24
8.0
3
8.5
0
9.0
3
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
MIDOSTAURIN
CHEMBL608533
Approved 2017
BOSUTINIB
CHEMBL288441
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

274
Total Assays
178
Tested Compounds
2
Assay Types
Binding — 272 assays, 178 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 209 158 7.0
assay format 27 15 6.9
subcellular format 20 0
cell-based format 16 5 7.6
Functional — 2 assays, 90 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 89 5.6
cell-based format 1 1 8.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine